2024 预见 ASCO | 肺癌领域中国之声一文速览

前言

一年一度的肿瘤界“奥斯卡”——2024年美国临床肿瘤学会（ASCO）年会将于当地时间5月31日-6月4日在美国芝加哥盛大召开，日前摘要题目已经公布。本次ASCO大会上，中国学者在肺癌领域的研究数量再创新高，一起来看看有哪些吧！

口头报告

摘要号：8004

Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): A randomized phase 3 trial.

可切除EGFR突变II-IIIA期非小细胞肺癌（NSCLC）接受12个月或6个月的埃克替尼辅助治疗对比辅助化疗后观察：一项随机III期试验（ICTAN，GASTO1002）

讲者：王思愚（中山大学肿瘤防治中心）

摘要号：8008

A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy (GASTO-1091).

一项评估局部晚期NSCLC新辅助化疗联合纳武利尤单抗和同步放化疗后纳武利尤单抗巩固治疗的II期随机试验（GASTO-1091）

讲者：刘慧（中山大学肿瘤防治中心）

摘要号：8009

Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer.

台湾地区对于重度吸烟以及有肺癌家族史的非吸烟人群肺癌早期检测计划

讲者：Pan-Chyr Yang（台湾大学医学院）

摘要号：8502

Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.

II期OptiTROP-Lung01研究：Sacituzumab tirumotecan（SKB264/MK-2870）联合KL-A167（抗PD-L1）作为中晚期NSCLC患者的一线治疗

讲者：方文峰（中山大学肿瘤防治中心）

摘要号：8508

Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial.

依沃西单抗联合化疗治疗接受EGFR-TKI治疗进展的EGFR突变非鳞状NSCLC患者：一项随机、双盲、多中心、III期试验（HARMONi-A）

讲者：张力（中山大学肿瘤防治中心）

临床科学研讨会

摘要号：LBA8509

KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

III期KRYSTAL-12研究：adagrasib对比多西他赛治疗经治的KRAS G12C突变晚期/转移性NSCLC患者

讲者：莫树锦（香港中文大学）

快速口头摘要会议

摘要号：8014

Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.

阿得贝利单抗联合化疗和序贯胸部放疗作为广泛期小细胞肺癌（ES-SCLC）的一线治疗的总生存期（OS）

讲者：陈大卫（山东第一医科大学附属肿瘤医院）

摘要号：8513

A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study.

舒沃替尼治疗含铂化疗失败的EGFR exon 20ins NSCLC：一项国际多中心注册临床研究，WU-KONG1研究的初步分析结果

讲者：杨志新（中国国立台湾大学肿瘤中心医院）

摘要号：8520

Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study.

taletrectinib治疗晚期或转移性ROS1阳性NSCLC患者的疗效和安全性：II期TRUST-I研究

讲者：李玮（上海市肺科医院）

壁报

摘要号：8024

A phase II study of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).

替雷利珠单抗（TIS）和化疗新辅助治疗可切除的IIIA/IIIB期NSCLC的II期研究

讲者：Ting Wang

摘要号：8027

Investigation of the role of personalized molecular residual disease in the assessment of high-risk non-small cell lung cancer (NSCLC) post-operation.cancer: A systematic review and meta-analysis of randomized clinical trials.

个体化MRD在高危NSCLC术后评估中的作用研究：一项随机临床试验的系统回顾和荟萃分析

讲者：Yu-Heng Zhou（中山大学肿瘤防治中心）

摘要号：8044

Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial.

PD-1抗体联合铂类双联化疗诱导治疗局部晚期NSCLC：一项随机对照、开放标签的II期临床试验

讲者：Suyu Wang（同济大学附属上海市肺科医院）

摘要号：8048

Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer.

随机II期neoSCORE试验的最终生存结果和探索性生物标志物分析：信迪利单抗联合化疗新辅助治疗可切除NSCLC两个周期与三个周期的比较

讲者：邱福铭（浙江大学医学院附属第二医院）

摘要号：8054

Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.

大分割放疗联合帕博利珠单抗和化疗新辅助治疗可切除的NSCLC：一项Ib期研究

讲者：丁乃昕（南京医科大学附属肿瘤医院）

摘要号：8058

The safety and efficacy of induction chemoimmunotherapy in initially unresectable stage III non-small cell lung cancer.

诱导化学免疫治疗在不可切除的III期NSCLC中的安全性和有效性

讲者：Min Tang（中国医学科学院老年医学研究所国家老年医学中心）

摘要号：8062

Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials.

安罗替尼联合多西紫杉醇治疗晚期NSCLC的免疫治疗进展：两项随机试验的汇总分析

讲者：Lin Wu

摘要号：8065

A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).

在局部晚期NSCLC中，新辅助化疗联合替雷利珠单抗±贝伐珠单抗，然后进行大分割放疗，同时化疗和巩固免疫治疗的II期双队列研究（GASTO-1086）

讲者：邱波（中山大学肿瘤防治中心）

摘要号：8073

Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.

新辅助化学免疫疗法治疗不可切除的III期NSCLC后序贯手术切除的疗效和手术安全性

讲者：Yana Qi（山东省肿瘤医院）

摘要号：8077

Phase I trial of aurora kinase A (AURKA) inhibitor VIC-1911 plus osimertinib for TKI-resistant, EGFR-mutant non-small cell lung cancer (NSCLC).

aurora激酶A（AURKA）抑制剂VIC-1911联合奥希替尼治疗TKI耐药、EGFR突变NSCLC的I期临床试验

讲者：Shen Zhao（中山大学肿瘤防治中心）

摘要号：8081

EGFR-TKI as neoadjuvant treatment in patients with NSCLC with EGFR sensitive mutation: A retrospective real-world analysis.

EGFR-TKI作为EGFR敏感突变NSCLC患者的新辅助治疗：一项回顾性现实世界分析

讲者：Sangtian Liu（广州医科大学第一附属医院）

摘要号：8082

Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial.

新辅助SHR-1701在不可切除的III期NSCLC中有或没有化疗：概念验证II期试验（TRAILBLAZER）中手术转换结果的有效性，安全性和可行性

讲者：吴一龙（广东省人民医院）

摘要号：8086

Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched study.

PD-L1抑制剂与PD-1抑制剂用于ES-SCLC的一线治疗：倾向评分匹配研究

讲者：田亚如（山东省肿瘤医院）

摘要号：8089

Tifcemalimab combined with toripalimab and chemotherapy as 1st line treatment for extensive-stage small cell lung cancer (ES-SCLC): A phase Ib/II, open-label study

Tifcemalimab联合特瑞普利单抗和化疗作为ES-SCLC的一线治疗：Ib/II期开放标签研究

讲者：虞永峰（上海市胸科医院）

摘要号：8093

ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC).

ARTEMIS-001:HS-20093在复发性SCLC患者中的Ia/b期研究数据

讲者：王洁（中国医学科学院肿瘤医院）

摘要号：8095

Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer.

抗PD-L1联合化疗治疗ES-SCLC的III期临床试验结果

讲者：陆舜（上海交通大学附属胸科医院）

摘要号：8098

A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer.

LS-SCLC同步放化疗后特瑞普利单抗巩固或观察的随机II期研究

讲者：邱波（中山大学肿瘤防治中心）

摘要号：8100

Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.

斯鲁利单抗与安慰剂联合化疗作为ES-SCLC一线治疗的比较：国际ASTRUM-005III期研究的延伸随访结果和患者报告结果

讲者：程颖（吉林省肿瘤医院）

摘要号：8102

An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC).

ATR抑制剂SC0245联合伊立替康治疗复发难治性ES-SCLC的开放标签、多中心、Ib/II期研究

讲者：虞永峰（上海市胸科医院）

摘要号：TPS8117

Efficacy and safety of aumolertinib combined with or without chemotherapy as an adjuvant treatment for stage II-IIIA non-small cell lung cancer following complete tumour resection: The first third-generation EGFR-TKI versus chemotherapy phase III clinical study (APEX).

阿美替尼联合或不联合化疗辅助治疗完全切除后II-IIIA期NSCLC的疗效和安全性：第一个第三代EGFR-TKI对比化疗的III期临床研究（APEX）

讲者：Feng Tan（中国医学科学院北京协和医学院肿瘤医院）

摘要号：TPS8120

Neoadjuvant toripalimab plus chemotherapy for resectable stage II-IIIB non-squamous non-small cell lung cancer with EGFR mutations: A multi-center, multi-cohort, exploratory study.

新辅助特瑞普利单抗联合化疗治疗EGFR突变的可切除II-IIIB期非鳞状NSCLC：一项多中心、多队列、探索性研究

讲者：Sida Cheng（北京大学人民医院）

摘要号：TPS8131

A phase II exploratory trial of adebrelimab in combination with chemotherapy and concurrent radiotherapy as a first-line treatment for oligo-metastatic extensive-stage small-cell lung cancer.

adebrelimab联合化疗和同步放疗作为寡转移性ES-SCLC的一线治疗的II期探索性试验

讲者：董忠谊（南方医科大学南方医院放射肿瘤科）

摘要号：8533

A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.

评估PM8002（一种靶向PD-L1和VEGF-A的双特异性抗体）作为晚期NSCLC患者的单一疗法的安全性和有效性的Ib/IIa期试验

讲者：吴春娇（吉林省肿瘤医院）

摘要号：8542

MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy.

MEK抑制剂联合RTK抑制剂（曲美替尼联合安罗替尼）治疗非G12C KRAS突变型NSCLC：一种新策略

讲者：韩宝惠（上海市胸科医院）

摘要号：8546

Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.

Mefatinib作为EGFR突变阳性NSCLC的一线治疗：III期疗效和生物标志物研究

讲者：Jia Yu（上海市肺科医院）

摘要号：8548

Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.

Dato-DXd在中国晚期或转移性NSCLC患者中的应用：I/II期TROPION-PanTumor02研究结果

讲者：Yuping Sun

摘要号：8554

Phase Ib clinical study of first-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous non-small cell lung cancer with EGFR mutation.

吉非替尼联合贝伐珠单抗和化疗一线治疗EGFR突变的晚期非鳞状NSCLC的Ib期临床研究

讲者：熊艳娟（天津医科大学肿瘤医院）

摘要号：8557

Efficacy and safety of vebreltinib in patients with advanced NSCLC harboring MET exon 14-skipping: Results of 2.5-year follow-up in KUNPENG.

伯瑞替尼治疗MET外显子14跳跃突变晚期NSCLC的疗效和安全性：KUNPENG研究2.5年随访结果

讲者：Jin-Ji Yan

摘要号：8563

Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.

舒沃替尼治疗EGFR外显子20插入突变的NSCLC患者血浆ctDNA生物标志物研究

讲者：Mengzhao Wang

摘要号：8587

High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.

高剂量伏美替尼治疗EGFR突变NSCLC和软脑膜转移患者：一项真实世界的研究

讲者：陈海洋（河南省肿瘤医院）

摘要号：8604

Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)

EGFR/c-MET双特异性抗体MCLA-129在晚期NSCLC中的疗效和安全性

讲者：王洁（中国医学科学院肿瘤医院）

摘要号：8605

Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study.

ifebemtinib（IN10018）联合D-1553治疗KRAS G12C突变NSCLC的安全性和有效性：Ib/II期研究的结果

讲者：Zaiqi Wang

摘要号：8606

Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.

Amivantamab联合化疗对比化疗作为EGFR外显子20插入突变晚期NSCLC的一线治疗：PAPILLON 研究中国亚组分析

讲者：唐可京（中山大学附属第一医院）

摘要号：8609

Efficacy and safety of bronchial arterial chemoembolization (BACE) in combination with tislelizumab for non-small cell lung cancer (NSCLC): A phase II study.

支气管动脉化疗栓塞（BACE）联合替雷利珠单抗治疗NSCLC的疗效和安全性：II期研究

讲者：段旭华（郑州大学第一附属医院）

摘要号：TPS8656

A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01).

telisotuzumab vedotin与多西紫杉醇治疗c-Met过表达、EGFR野生型、局部晚期/转移性非鳞状NSCLC（TeliMET NSCLC-01）患者的III期全球研究

讲者：陆舜（上海交通大学附属胸科医院）

摘要号：TPS8662

TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations

TOP研究：一项III期、多中心、随机对照研究，奥希替尼联合卡铂和培美曲塞对比奥希替尼单药治疗伴有EGFR和TP53突变的晚期非鳞状NSCLC患者的疗效

讲者：杨云鹏（中山大学肿瘤防治中心）

备注：

排名不分先后，按照摘要号进行排序

如有遗漏或任何问题，请给我们留言~

编辑：Squid

排版：KIKI、Squid

执行：Squid

医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。

本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。